Clin Osteol 2015; 20(1): 15-20

Paget's disease of bone?Review articles

M. Skácelová, P. Horák, E. Dokoupilová, E. Kačerová, J. Škarda

After osteoporosis, Paget's disease is the second most common type of metabolic skeletal disorders. It is primarily characterized by im­ paired osteoclast function. It is a localized disease of bone remodeling (occurring only in certain skeletal regions, unlike systemic me­ tabolic bone diseases). The etiology is unknown. Chaotic bone remodeling occurs, with formation of poor quality bone of cotton wool appearance. The disease is mostly asymptomatic, with patients being examined for elevated serum levels of alkaline phosphatase. The clinical manifestations are dominated by pain at the site of bone involvement and development of deformities. The complications in­ clude fractures, pressure syndromes or relatively rare progression to osteosarcoma. The drugs of choice are bisphosphonates. Under certain circumstances, the differential diagnosis of the disease may be difficult as it must be distinguished from other conditions as­ sociated with localized bone remodeling, in particular primary or secondary bone tumors. The authors present a case of a 65-year-old female patient with clinically highly suspected Paget's disease of bone gnosed with B cell lymphoma responding well to therapy

Keywords: Paget's disease ofbone, alkaline phosphatase, bisphosphonates

Published: June 11, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skácelová M, Horák P, Dokoupilová E, Kačerová E, Škarda J. Paget's disease of bone? Osteologický bulletin. 2015;20(1):15-20.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Belada M, Trněný M a kol. Diagnostické a léčebné postupy u nemocných s m ními lymfomy, osmé doplněné a přepracované vydání. 2014. www.lymphoma.cz
    2. Altman RD, Bloch DA, Hochberg MC, Murphy WA Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000;15:461. Go to original source...
    3. Gennari L, Di Stefano M, Merlotti D e in Italy. J Bone Miner Res 2005;20:1845. Go to original source...
    4. van Staa TP, Selby P, Leufkens HG et al. Incidence and natural history of disease of bone in England and Wales. J Bone Miner Res 2002;17:465. Go to original source...
    5. Štěpán J. P^getova kostní choroba, Revmatologie; Maxdorf 2012. pp.557-562.
    6. Chung PY, Beyens G, Boonen S et al. The majority of the genetic risk for Pag disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet 2010;128:615. Go to original source...
    7. Albagha OM, Visconti MR, Alonso N et al. Genome-wide association study iden­ tifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet 2010;42:520. Go to original source...
    8. Rea SL, Walsh JP, Ward L et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bo­ ne with a severe phenotype. J Bone Miner Res 2006;21:1136. Go to original source...
    9. Friedrichs WE, Reddy SV, Bruder JM et al. Sequence analysis of measles virus nucleoc 17:145.
    10. Reddy SV, Kurihara N, Menaa C et al. Osteoclasts formed by measles virus-in­ fected osteoclast precursors from hCD46 transgenic m of pagetic osteoclasts. Endocrinology 2001;142:2898. Go to original source...
    11. Bastin S, Bird H, Gamble G, Cundy T. Paget's disease of bone-becoming a rari See comment in PubMed Commons below Rheumatology 2009;48(10): 1232-1235. Go to original source...
    12. Wermers RA, Tiegs RD, Atkinson EJ et al. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J Bone Miner Res 2008; 23:819. Go to original source...
    13. Seton M. Paget's disease of bone. In: Rheumatology, 4th, Hochberg MC, Silman AJ, Smolen JS et al. (Eds), Mosby (Elsevier), Philadelphia 2008; p 2003.
    14. Josse RG, Hanley DA, Kendler D et al. se of bone. Clin Invest Med 2007;30:E210. Go to original source...
    15. Whyte MP. Clinical practice. Paget's disease of bone. N Engl J Med 2006;355:593. Go to original source...
    16. Selby PL. Guidelines for the diagnosis and management of Paget's disease perspective. J Bone Miner Res 2006; 21 Suppl 2:P92. Go to original source...
    17. Griffiths HJ. Radiology of Paget's disease. Curr Opin Radiol 1992;4:124.
    18. Mulligan ME, McRae GA, Murphey MD. Imaging features of primary lymphoma of bone. AJR Am J Roentgenol 1999;173:1691. Go to original source...
    19. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget's di­ sease of bone: indications for Miner Res 2006; 21 Suppl 2:P94. Go to original source...
    20. Ralston SH, Langston AL, Reid I sease of bone. Lancet 2008;372:155. Go to original source...
    21. Seton M, Krane SM. Use of zo Ther Clin Risk Manag 2007;3:913.
    22. Reid IR, Miller P, Lyles K et al. Comparison of a single infusion acid with risedronate for Paget's disease. N Engl J Med 2005;353:898. Go to original source...
    23. Alvarez L, Peris P, Guanabens N et al. Long-term biochemical response after b phosphonate therapy in Paget's disease ofbone. Proposed intervals for monitoring treatment. Rheumatology 2004;43:869. Go to original source...
    24. Miller PD, Brown JP, Siris ES et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med 1999;106:513. Go to original source...
    25. Walsh JP, Ward LC, Stewart GO et al. A randomized clinical trial comparing alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 2004;34:747. Go to original source...
    26. Schwarz P, Rasmussen AQ, Kvist TM, Andersen UB, J0rgensen NR. Paget's di­ sease of the bone after treatment with Denosumab: a case report. Bone. 2012; 50(5):1023-1025. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.